Releases


All 2014 Releases
Jul 28, 2014 Envarsus® Receives European Marketing Authorization for Treatment of Both Kidney and Liver Transplant Patients  
Jul 28, 2014 Envarsus® får EMA markedføringstilladelse til behandling af såvel nyre- som levertransplantationspatienter  
Jun 30, 2014 Envarsus® XR Demonstrates Lower Treatment Failure Rate in African-Americans Compared to Twice-Daily Tacrolimus (Prograf®)  
Jun 30, 2014 Envarsus® XR viser lavere forekomst af behandlingssvigt i afroamerikanere sammenlignet med to-gange-daglig tacrolimus (Prograf®)  
Jun 23, 2014 Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients  
Jun 23, 2014 Veloxis offentliggør positive 2-års resultater af pivotalt fase III studie af Envarsus® XR (tacrolimus extended-release tabletter) i de novo nyretransplantationspatienter  
Jun 3, 2014 Veloxis Announces Senior Level Appointments in Preparation for U.S. Commercialization of Envarsus® XR (tacrolimus extended-release tablets)  
May 22, 2014 Warrantordning - Nye vedtægter  
May 22, 2014 Warrant Programme - New Articles of Association  
May 22, 2014 Veloxis modtager positiv udtalelse fra CHMP for Envarsus® til behandling af såvel nyre- som levertransplantationspatienter  
May 22, 2014 Veloxis Receives Positive Opinion from CHMP for Envarsus® for Treatment of Both Kidney and Liver Transplant Patients  
May 14, 2014 Veloxis Pharmaceuticals A/S establishes new Warrant Programme  
May 14, 2014 Veloxis Pharmaceuticals A/S etablerer warrantordning  
May 14, 2014 Veloxis Pharmaceuticals announces financial results for the first three months of 2014  
May 6, 2014 Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 1. kvartal 2014 — resultater fra 1. januar til 31. marts 2014  
May 6, 2014 Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for first Quarter 2014 — results from 1 January to 31 March, 2014  
Apr 28, 2014 Veloxis Announces Scientific Publication of Phase II Study Demonstrating Conversion from Twice-Daily Tacrolimus to Once-Daily Envarsus® in Liver Transplant Patients  
Apr 28, 2014 Veloxis Announces Scientific Publication of Phase II Study Demonstrating Conversion from Twice-Daily Tacrolimus to Once-Daily Envarsus® in Liver Transplant Patients  
Apr 9, 2014 Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting  
Apr 9, 2014 Veloxis Pharmaceuticals A/S - Forløb af ordinær generalforsamling  
Mar 25, 2014 Warrantordning - Nye vedtægter  
Mar 25, 2014 Warrant Programme - New Articles of Association  
Mar 20, 2014 Warrant Programme - Registration of capital increase and new Articles of Association following warrant exercise  
Mar 20, 2014 Warrant Program - Registrering af kapitalforhøjelse og nye selskabsvedtægter i forlængelse af warrantudnyttelse  
Mar 20, 2014 Warrantprogram - Veloxis Pharmaceuticals A/S udsteder nye aktier i forbindelse med udnyttelse af warrants og indberetning af aktietransaktioner af nuværende og tidligere medarbejdere i Veloxis Pharmaceuticals A/S  
Mar 20, 2014 Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants and announces trading in the company's shares by current and former employees  
Mar 17, 2014 Indkaldelse til ordinær generalforsamling  
Mar 17, 2014 Notice to Convene Annual General Meeting  
Mar 14, 2014 Korrektion: Den amerikanske lægemiddelmyndighed FDA accepterer Veloxis' registreringsansøgning (New Drug Application) for Envarsus® til forebyggelse af organafstødning i nyretransplantationspatienter  
Mar 14, 2014 Correction: U.S. FDA Accepts Veloxis' New Drug Application for Envarsus® for the Prevention of Organ Rejection in Kidney Transplant Patients  
Mar 14, 2014 Veloxis Pharmaceuticals A/S etablerer warrantordning  
Mar 14, 2014 Veloxis Pharmaceuticals A/S establishes new Warrant Programme  
Mar 13, 2014 U.S. FDA Accepts Veloxis' New Drug Application for Envarsus® for the Prevention of Organ Rejection in Kidney Transplant Patients  
Mar 13, 2014 Den amerikanske lægemiddelmyndighed FDA accepterer Veloxis' registreringsansøgning (New Drug Application) for Envarsus® til forebyggelse af organafstødning i nyretransplantationspatienter  
Mar 6, 2014 Veloxis Promotes John Weinberg to Chief Operating Officer  
Mar 6, 2014 Veloxis forfremmer John Weinberg til Chief Operating Officer  
Mar 5, 2014 Veloxis Pharmaceuticals publishes Annual Report 2013  
Mar 5, 2014 Veloxis Pharmaceuticals offentliggør årsrapport 2013  
Mar 3, 2014 Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af årsrapporten 2013 — resultater fra 1. januar til 31. december 2013  
Mar 3, 2014 Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual report 2013 — results from 1 January to 31 December, 2013  
Jan 8, 2014 Veloxis Pharmaceuticals modtager patentgodkendelse fra den amerikanske patentmyndighed på indgivelse af Envarsus® uafhængig af tidspunkt på døgnet  
Jan 8, 2014 Veloxis Pharmaceuticals Receives Notice of Allowance from U.S. Patent Office for Diurnal-Independent Administration of Envarsus®  
Showing 1-42 of 42 Page: 1  
=add release to Briefcase